about
Novel vaccine development strategies for inducing mucosal immunityAlphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challengeThermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugsBroad-Spectrum Drugs Against Viral AgentsComparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IABImmunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.Invariant NKT cells sustain specific B cell responses and memory.The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positiveTranscriptome profiles associated to VHSV infection or DNA vaccination in turbot (Scophthalmus maximus)Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse modelPrevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriersTLR9 is critical for glioma stem cell maintenance and targeting.Mucosal and systemic adjuvant activity of alphavirus replicon particles.Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes.Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infectionFusion with extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 leads to enhancement of immunogenicity of Hantaan virus DNA vaccines in C57BL/6 mice.Detection of innate immune response modulating impurities in therapeutic proteinsA novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in agingThe Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice.Effects of adjuvants on IgG subclasses elicited by virus-like particles.Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.Polyethyleneimine-functionalized boron nitride nanospheres as efficient carriers for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides.Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.Formulation of vaccines containing CpG oligonucleotides and alumFrom mice to humans - murine intelligence for human CD8+ T cell vaccine design.Regulators of apoptosis: suitable targets for immune therapy of cancer.Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.The potential of antibody-mediated immunity in the defence against biological weapons.Role of microglia in the central nervous system's immune response.Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.Liposome-nucleic acid immunotherapeutics.Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c miceCpG Oligodeoxynucleotide Inhibits Cockroach-Induced Asthma via Induction of IFN-γ⁺ Th1 Cells or Foxp3⁺ Regulatory T Cells in the Lung.Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.
P2860
Q24607533-39980C42-1373-4A5A-A5A5-779571B432F6Q24657762-C6F53CDD-D420-4582-B35C-44B67CAE53C1Q24811712-60C1A133-C488-44DE-BCB5-48C098D29786Q27487859-51664294-8291-47EF-BC39-358847842F77Q27490878-616146EC-8792-4C72-865B-28A5DE62350DQ30423481-51AEECCA-5CC6-4757-BB1E-9E26D70773F8Q30479030-4FA47166-723B-467F-A7A4-103D7D51D1D3Q31171481-5DD5652C-76BD-4114-B2E2-6E6A299C819CQ33759497-6B81FFC1-1C06-40F1-AFD2-076EE15B3C57Q33784812-96B5C2B3-9EBE-4FB1-AD16-ADC7D938D813Q33826107-CD61646A-F444-457F-BDF2-16A8A24FEE0EQ34011343-C2A9A2CF-9708-448D-AC5B-5EF9F5870CD7Q34105207-D9CD2156-D1FA-4190-9A1D-19FF3A73BA74Q34123184-C143ACE4-64B8-453B-B102-62F6B7C2DE41Q34180043-AE0CE3A4-534F-4120-9B3B-7DD2F92A70B2Q34200500-A71307E5-610A-4625-8447-9C08B8C867E7Q34204722-E085A787-007D-444F-B15F-04C49D1A802AQ34410789-5EC37B86-0347-4D42-871E-E63CFECB6425Q34721210-E5C1706C-8D28-420D-9DA4-03DE07C391FEQ35083138-B74BA71C-271A-4ED7-AAF7-1013CA6C2E16Q35478235-77CC77B2-D3B3-4A31-9D8A-D16B15B16262Q35611430-0019AAF7-A42F-4E71-A783-8CF6978E015FQ35661214-9DCDED1F-AB5D-4FDB-A75A-D7A59743394EQ35757996-47398CAC-976F-40A5-BAF9-2B73ACFD1654Q35848642-0934BA6D-DF62-4FC3-98C0-A6F03BFB732DQ35940681-49BB5A1B-7EB6-4101-8839-4C5A3D3ABA92Q36010351-5F90CBC8-07D5-48F9-AD6B-A589AD94D22BQ36019395-89B545BE-2160-4C5B-A6B9-4E152A28B572Q36026296-9B36019B-FD2A-4F4B-8257-10F22A3D5127Q36065972-4B14B190-2D63-4E4F-A3F9-B54E2BB4E222Q36111911-1FC723E0-523B-4601-83E6-DAD51A7706C1Q36198661-A0322CDF-83F8-436E-8D93-07EA5B7AFE67Q36273411-5802D3C7-517F-4C0C-A492-1B57BA202A08Q36273686-29315A90-6F87-4AA3-A7C9-89B0909C46D8Q36313996-C899CD9E-F7AB-4ED1-AC16-92D823F214D5Q36378325-6886BABC-D1FE-4209-9B16-AC877C408D80Q36517160-77DA9270-A951-4459-8497-3E1570A75610Q36539044-E56D9B33-5D66-4A43-A495-17204BE2F9F7Q36636607-58FBE9AC-0BB9-4359-B81F-CB9B881E60CBQ36652638-FAFF221F-E19B-4AB1-B347-BA92E48EDDAD
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Use of CpG oligodeoxynucleotides as immune adjuvants.
@ast
Use of CpG oligodeoxynucleotides as immune adjuvants.
@en
type
label
Use of CpG oligodeoxynucleotides as immune adjuvants.
@ast
Use of CpG oligodeoxynucleotides as immune adjuvants.
@en
prefLabel
Use of CpG oligodeoxynucleotides as immune adjuvants.
@ast
Use of CpG oligodeoxynucleotides as immune adjuvants.
@en
P2093
P2860
P1476
Use of CpG oligodeoxynucleotides as immune adjuvants.
@en
P2093
Daniela Verthelyi
Debra Currie
Dennis M Klinman
Ihsan Gursel
P2860
P304
P356
10.1111/J.0105-2896.2004.00148.X
P577
2004-06-01T00:00:00Z